The stock of Travere Therapeutics Inc (NASDAQ:TVTX) last traded at $17.11, down -2.73% from the previous session.
TVTX stock price is now 47.18% away from the 50-day moving average and 93.88% away from the 200-day moving average. The market capitalization of the company currently stands at $1.31B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $25, Guggenheim recently Upgraded its rating from Neutral to Buy for Travere Therapeutics Inc (NASDAQ: TVTX). , while ‘Citigroup’ rates the stock as ‘Buy’
In other news, LYONS GARY A, Director sold 40,000 shares of the company’s stock on Oct 04 ’24. The stock was sold for $589,101 at an average price of $14.73. Upon completion of the transaction, the Director now directly owns 51,000 shares in the company, valued at $0.87 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 04 ’24, Officer GARY A LYONS bought 40,000 shares of the business’s stock. A total of $546,000 was incurred on buying the stock at an average price of $13.65. A total of 1.51% of the company’s stock is owned by insiders.
During the past 12 months, Travere Therapeutics Inc has had a low of $5.12 and a high of $17.77. As of last week, the company has a debt-to-equity ratio of 26.62, a current ratio of 3.04, and a quick ratio of 2.99. The fifty day moving average price for TVTX is $11.6254 and a two-hundred day moving average price translates $8.8249 for the stock.
The latest earnings results from Travere Therapeutics Inc (NASDAQ: TVTX) was released for 2024-06-30. The net profit margin was -209.36% and return on equity was -582.60% for TVTX. The company reported revenue of $54.12 million for the quarter, compared to $32.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 68.08 percent. For the current quarter, analysts expect TVTX to generate $60.87M in revenue.
